Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025

Core Insights - Incyte is set to present data on its TGFR2×PD-1 bispecific antibody and KRAS G12D inhibitor at the ESMO Congress 2025 [1] Group 1 - The presentation will focus on the efficacy and safety profiles of the bispecific antibody and the KRAS G12D inhibitor [1]